The new aids will make their debut at this month's Vet Festival (20-21 May 2022, Loseley Park, Surrey).
The Flexi-Wedge (pictured) positioning aid aims to deliver both better quality and easier to interpret imaging, and to facilitate the ideal positioning of surgical patients.
The second product is the Saddle-Sandbags, which The Big Dog Bed Company says address two problems – the need to hold a patient in place without loading weight to any part of the body and the tendency of existing sandbags to leak sand after a few months of manipulation to different shapes.
Dru Ross, Director at Big Dog Bed Company said: “Support wedges are obviously widely used in the veterinary field.
"The difference with the design of the Flexi-Wedge is that they can be held securely in the desired position and are fully adjustable, making them suitable for a wide range of patient size and shape”.
“The Saddle-Sandbag is designed for those situations when a limb needs to be held out securely without any load on it and standard sandbags are not suited to this purpose.
"There is no need to manipulate the sandbag to the desired shape.
"The weight is split between two bags joined by a broad central strap so the strap is placed round or over the limb”.
James Weston, Managing Director at Northwest Referrals was one of the first to use the Flexi-Wedge.
James said: “I’ve never had such a straight spine when scanning a greyhound before using these supports. Every CT scanner should be sold with these”.
Patrick Harte MRCVS from the The Sidings Veterinary Surgery said: “The weighted ends make these sandbags much easier to handle.
"The larger aid is excellent for holding upper thoracic limb out of the way for lateral views of the elbow, for instance and the width of the flat part of the aid is perfect for wrapping around the antebrachium of the thoracic limb.”
The Flexi-Wedges and the Saddle-Sandbag products use waterproof, antibacterial, wipe clean fabrics in which the seams are thermally welded so no moisture can enter and no sand can escape.
The Flexi-Wedges are available in two lengths 60cm and 90 cm.
They are supplied with wipe clean straps that can be tailored to the size of table on which they are used.
The Saddle-Sandbags are available in three sizes.
The consultation, which was held by the College early in 2017, asked for the views of veterinary surgeons and nurses, animal owners, and stakeholders on the use of telemedicine in veterinary clinical practice.
The consultation was designed to help identify potential risks associated with telemedicine, identify areas where it may help address the needs of both clinicians and the public, and support the potential development of new professional standards and guidance.
The online survey of veterinary professionals received 1,230 responses, while the public consultation received 229 responses and the survey of organisations/stakeholders received eight responses.
The headline question asked of veterinary professionals was whether RCVS 'supporting guidance to the Code of Professional Conduct' should be amended to allow remote examination to take the place of physical examination in certain circumstances. 41% said 'Yes', 40% said 'No' and 18% were unsure.
Veterinary professionals and organisations were then asked a series of questions in order to establish how they rated the risk associated with telemedicine according to activity type, practice type, clinical sign or syndrome, mode of technology, and familiarity with client, animal or environment.
Unsurprisingly perhaps, the majority felt that providing just general advice presented a low risk. At the other end of the scale, most felt that the use of telemedicine to diagnose disease or injury would be either 'high risk', or 'not appropriate at all'.
Likewise, the majority said the risks would be low or medium where the client and environment were known and the animal seen before, for the same problem. By contrast, the majority said telemedicine would be either 'high risk' or 'not appropriate at all' when the client, animal and environment were all unknown.
When asked whether the current definition of 'under care' should be extended to allow veterinary surgeons to prescribe veterinary medicines where there has been no physical examination of the animal, 69% said 'No', 16% said 'Yes' and 15% were unsure.
However, when asked whether certain types of veterinary medicines should be able to be prescribed without a physical examination of the animal, the majority of respondents to the professional survey (52%) were in favour.
The results of the consultation were first considered at a special meeting of the Standards Committee in August 2017, where it was noted how the consultation had revealed significant confusion around current supporting guidance to the RCVS Code of Professional Conduct and that, at a minimum, clarification as to what was currently permissible was needed.
The Committee determined a key issue going forward was whether to change the Supporting Guidance to the RCVS Code of Professional Conduct regarding 'under care' to allow veterinary surgeons to prescribe POM-V medicines based on telemedicine alone.
Given the complex nature of the issues and the wide-ranging implications, the Standards Committee presented a range of options for amending RCVS Guidance to RCVS Council at its meeting in November 2017. After discussion, Council asked the Standards Committee to continue their review and to present more detailed proposals to Council regarding the future of telemedicine in clinical veterinary practice.
Anthony Roberts, RCVS Director of Leadership and Innovation, said: "We would like to thank all those who took the time to respond to the consultation – although Council has not yet made any firm decisions, we felt it would be useful to share our research so far.
"The use of telemedicine is growing rapidly in human healthcare and it is only right the RCVS assesses the opportunities it could bring to improve access to veterinary services. It is critical, however, that we understand the issues it presents 'at the coal face' and consider all the available evidence before making any changes to our Guidance. The RCVS should ensure its regulatory framework fosters innovation and maximises the opportunities to improve the quality, efficacy and accessibility of veterinary services, whilst at the same time protecting animal health and welfare."
The Standards Committee will meet again in April 2018 to take further evidence and develop proposals to take the issue forward.
Meanwhile, the full summary is available on the College’s website: www.rcvs.org.uk/telemeds-summary/.
Running in July, the campaign aims to raise awareness of hyperthyroidism in cats and hypothyroidism in dogs, educate pet owners to spot the symptoms and thereby encourage early diagnosis.
MSD Animal Health says it hopes the campaign will increase the number of pets being taken to their veterinary practice for diagnosis, and increase both return visits and treatment compliance.
Practices supporting Pet Thyroid Month will be supplied with resources to help them educate pet owners about the two conditions.
Caroline Darouj, product manager at MSD Animal Health, said: "Although hyperthyroidism in cats and hypothyroidism in dogs are well known conditions and diagnosis is generally straightforward, a large number of vets in Europe state that both disorders are under-diagnosed, due to the fact that pet owners don’t recognise the signs.
"We wanted to launch our Thyroid Month campaign to encourage pet owners to spot the early symptoms of thyroid issues in their pets and seek advice from their veterinary practices.
"Our aim is also to benefit and educate vets and vet nurses with regard to the use of Leventa and Vidalta in treating these manageable conditions in both dogs and cats."
To find out more about Pet Thyroid Month, visit www.vidalta.co.uk
Virbac has launched a new 12 month version of Suprelorin, the reversible medical castration implant for dogs, widening the options for clients seeking an alternative to surgical castration.
Product manager Chris Geddes MRCVS said: "The launch of Suprelorin 12 gives practices the chance to offer dog owners a more convenient castration option. The implant renewal can now be included with their dog's annual boosters or health check.
"The slow-release implant is inserted at the back of the neck in the same manner as a microchip. There is no anaesthetic, no surgery and no scarring. The current implant, which contains 4.7mg active and lasts for around 6 months after insertion, will continue to be available for those wanting a more brief solution or as a trial.
"Deslorelin is a GnRH superagonist which causes suppression of LH/FSH, and therefore testosterone production, leading to temporary infertility."
For further information on Suprelorin/12, please call and ask to speak to one of our veterinary advisors on 01359 243243, or contact your local Virbac territory manager.
CVS says the new hospital, which will be based at Central Park, Avonmouth, will be custom-built with uniquely designed facilities, state-of-the-art diagnostic tools such as MRI and CT scanners, and a cutting-edge stereotactic linear accelerator for radiotherapy in cancer treatment, the only one of its kind for pets in England.
The hospital, which will open next summer, will employ over 100 people led by a team of Specialist veterinary surgeons and supported by residents, interns and registered veterinary nurses.
Planning permission has been granted for the project, and CVS is now appointing building contractors.
Richard Fairman, CEO of CVS Group, said: "We are extremely excited to be developing this innovative new specialist veterinary hospital in Bristol, providing the best animal care to pet owners across the South West. With state-of-the-art equipment and some of the highest qualified veterinary professionals, we are confident that the site will act as a centre of excellence in the veterinary world, and be a leader in Europe for cancer treatments.
"The new hospital signals our commitment to investing in cutting-edge technology to bring cancer treatment in pets to the next level. It will provide a number of employment opportunities and secure specialist veterinary skills in the Bristol area. We look forward to finalising development plans and opening the doors to pet owners in 2022."
The strange phenomenon was spotted by Veterinary Vision's clinical director Chris Dixon when he examined Dachshund called Margo, which had been referred for the treatment of a corneal ulcer and fungal infection.
Chris said: “I was assessing Margo’s eye and was very surprised to see a face smiling back at me.
"It perhaps doesn't bear quite the same resemblance as the Turin Shroud. Still, I've never seen anything like it before.
"The good news is that it does not appear to have affected her vision at all.”
Apparently the smiling face is still there, even after Chris performed a corneal graft.
Chris added: "I think we can safely say that Margo is a very happy dog, both inside and out!"
During the webinar, which took place earlier this month, senior officers and staff from the College explained the new guidance, what it will mean for the profession, and answered questions submitted by delegates.
The webinar was chaired by RCVS President Dr Melissa Donald MRCVS with a panel comprising Standards Committee Chair Linda Belton MRCVS, RCVS Registrar Eleanor Ferguson, and RCVS Head of Standards Gemma Kingswell.
The webinar included an overview of the main changes, the considerations to take into account when prescribing POM-Vs remotely, the circumstances under which POM-Vs cannot be prescribed remotely, the prescription of antibiotics, antifungals, antiparasitics and antivirals, and how the guidance will be enforced.
Eleanor Ferguson, RCVS Registrar, said: “We have also now published a range of practice-based scenarios to help explain how the new guidance should be followed in various circumstances, and in relation to different species.
"These scenarios cover a variety of different situations, including how the guidance applies to two or more practices with mutual clients, consultancy services and the prescription of long-term controlled drugs.”
A second webinar will be held on Monday 17th July, with priority for those who wanted to attend the June webinar but were not able to do because it was over-subscribed.
www.rcvs.org.uk/undercare
The survey, which takes about 5 minutes (I timed it), is designed to canvas opinion about the priorities for learning and development.
Rich Casey, Junior Vice President of the VMG (pictured right), said: "From marketing to HR to financial planning and all points in between, today’s veterinary leaders require expertise in every aspect of running a successful business.
"We want to create a truly valuable, constructive and evidence-based CPD calendar for next year. Views from those working in the profession will help us to fully understand what good leadership and management look like in the veterinary world and we will then make sure that the programme promotes best practice in these important areas. We thank everyone who takes the time to complete the survey."
The survey can be accessed here: https://www.surveymonkey.co.uk/r/VETCPDPR
Kriptazen is supplied with a twist-adjustable and weight-graduated dosing pump which means farmers can administer a precise dose up to 60kg without having to calculate it in ml’s first. Virbac says this will help to reduce the risk of incorrect dosing and toxicity issues.
Virbac’s Technical Product Manager Rosie Naylor said: "We are delighted to bring Kriptazen to the market. The trusted active halofuginone, along with the innovative weight graduated dosing pump, provides practices with added peace of mind when it comes to treatment."
For more information, contact your Virbac Territory Manager.
Bayer Animal Health has launched Remend Wound Spray Gel for cats, dogs and horses.
The new gel contains Remend's structurally modified hyaluronic acid (HA). Bayer says it provides a matrix for cellular events that occur during the proliferative phase of the healing process, which has been shown to enhance healing1, and can promote rapid wound closure
Georgie Hollis BSc from www.vetwoundlibrary.com said: "Managing wounds can be challenging in veterinary practice; the progression of wound healing can be influenced by many factors, and selecting an appropriate product to apply should be based on the needs of the individual wound. A product that provides a moist healing environment and support of the proliferative phase ensures that cellular activity is optimised, helping to improve healing times and minimise scar tissue."
Bayer says Remend Wound Spray Gel is designed for use as part of the overall management of wounds; additional measures such as lavage, debridement and control of infection are equally important, as is giving consideration to any secondary factors that may delay healing if not addressed. The product aims to achieve greater compliance amongst owners by providing an effective management option that is easy to apply. A single application may be sufficient to enhance wound closure in fresh uncomplicated wounds; however more complex wounds may require multiple applications in order to accelerate closure.
For more information, visit: www.vetcentre.bayer.co.uk
References
Available for download now, the MobiVet Veterinary Formulary App is designed to make drug calculations and prescribing faster, easier and safer. It contains dose rate and interval data for over 250 drugs commonly used in small animal practice.
Searchable by drug name or trade names, with species-specific dosing information, the app calculates doses based on the patient type, weight, or body surface area as appropriate. MobiVet also provides a checklist of known relevant drug interactions for each medication, to prevent prescribing errors.
Stuart says an iOS version is in production.
To download the Android version, visit: https://play.google.com/store/apps/details?id=com.project.user.drug_formulary&hl=en
The study was part of a research project called VetCompass, through which the RVC, in collaboration with Vets Now, collects anonymised clinical information on over 6 million companion animals under veterinary care in the UK.
The study investigated bitches presented with difficulty giving birth (dystocia) from among almost 20,000 bitches attending 50 Vets Now surgeries. Researchers found that out of 20,000 bitches receiving emergency veterinary care, 3.7 per cent of these were treated because of difficulties encountered giving birth.
The most commonly affected breeds were the French Bulldog (15.9 times more likely), Boston Terrier (12.9 times more likely), Chihuahua (10.4 times more likely) and Pug (11.3 times more likely).
Dr Dan O’Neill, a companion animal epidemiologist within the VetCompass Programme, said: "Giving birth in dogs is not always a benign process and our research shows this risk is especially exacerbated in some common brachycephalic and toy breeds. Prospective owners should bear these welfare costs for high risk breeds in mind when choosing their new puppy."
Caroline Kisko, Kennel Club Secretary, said: 'VetCompass' research will not only enable dog breeders to make responsible breeding choices to improve the health of these dogs, it will help to highlight what puppy buyers need to be looking out for if they are intent on owning one of these breeds. If people are choosing a breed simply for its looks and are not going to a reputable breeder, they are likely to face high vet costs and a lifetime of heartache."
This study builds on previous 'purchasing' research by the RVC which found that appearance is the number one reason why owners purchase flat-faced breeds, even though their large, round, wide-set eyes, and flat rounded faces are linked with a variety of inherited diseases.
Dr Rowena Packer, lead author of the study and Research Fellow at RVC, said: "Potential puppy buyers attracted to the appearance of these breeds should seriously consider whether they are emotionally and financially prepared to take on a breed with high risks of health complications, and consider whether alternative, lower-risk breeds would better fit their lifestyle."
Virbac has announced the launch of Carprox Vet, a carprofen-based NSAID indicated for the alleviation of post-operative pain and inflammation following orthopaedic and soft tissue surgery in dogs and cats and for the treatment of chronic pain and inflammation in dogs.
Carprox is presented as a palatable tablet for dogs in three sizes - 20 mg, 50 mg and 100 mg. An injectable 50 mg/ml solution for dogs and cats has also been launched (in bottles of 20ml).
Virbac Marketing Manager for Companion Animals Simon Boulton MRCVS said: "We launched our meloxicam-based solution for acute and chronic pain, Inflacam, in 2013. With the arrival of Carprox Vet, we are now able to offer vets a carprofen-based alternative for added flexibility and choice. We are delighted to add it to our product range and are proud to say that Virbac now offers one of the widest ranges of products for the treatment of small animals in the UK."
In one case, Tigga, a 17-year-old cat with an itchy and destructive tumour on her nose, was in complete remission within 44 days. In another case, a tumour vanished in a dog where the aim of the treatment was only to shrink the mass before an operation to remove it.
NDSR, which is based in Bletchingley, is the only referral centre in the UK and one of very few in the world offering electrochemotherapy in pets.
Electrochemotherapy is given in two stages.
First, the patient is given a mild dose of intravenous chemotherapy in the normal way and then, using a probe, a precise electrical charge is given to the area on or around the tumour.
This temporarily opens up tiny holes in the cells, big enough to allow the drug to enter, which then close again in microseconds. This means the drug will only attack cancerous cells, unlike normal chemotherapy, which also kills healthy cells.
Gerry Polton, clinical director of oncology at NDSR, said: "Normal chemotherapy works on the principle of being more damaging to cancer than non-cancerous tissue. Some cancers are more resilient, so there are differences in how they respond to treatment, and this can cause more harm to the patient.
"Electrochemotherapy involves clever anatomical targeting of a specific site and is an effective way of protecting healthy cells.
"The results we are seeing in cases like Tigga’s are unprecedented and we are learning about the procedure all the time. We are always looking for better ways of treating cancer without the effect of harming the patient indiscriminately and this has proved to be a very effective way of doing this."
According to NDSR, the results could help inform the development of the targeted treatment in humans, where electrochemotherapy is used in a small number of cases in the NHS.
At present, many clinical trials are carried out on laboratory animals which are bred with no immune system – but dogs have similarities in genetics to humans and have working immune systems, meaning they can provide a more accurate parallel for how the treatment may work in people.
Gerry said: "A pet dog would be a good model for human cancer studies. It's a mammal with a heartbeat, blood supply and working immune system.
"Progress with electrochemotherapy in animals is being made in parallel with progress in electrochemotherapy in the human field, and what we are learning may even inform what is happening in people.
"Electrochemotherapy is a form of treatment which Cancer Research UK describe as 'fairly new' on its website, with limited information about its effectiveness. So maybe something would be gained from learning together."
Working in collaboration with researchers at University of Texas, Southwestern (UTSW) Medical Center, the team has succeeded in using gene editing techniques on dogs to restore the expression of the dystrophin protein that is absent in DMD patients’ muscles to levels that could be life changing.
DMD is the most common, fatal, genetic disease that affects children. The same disorder also occurs in many dog breeds. It is caused by mutations in the gene that encodes dystrophin, a crucial protein that helps protect muscle fibres and the heart when they contract. Patients with the disease produce effectively no dystrophin protein, so their muscles and heart become damaged during contraction, leading to inability to walk, skeletal deformities, breathing problems and heart failure. Patients with DMD have a life expectancy that does not go far beyond their twenties.
Researchers say that this preliminary research, published in Science, demonstrates an approach that could lead to an effective, in principle one-time treatment for DMD for the most common genetic mutations affecting human patients. Through a single intravenous injection, researchers have been able to modify the dystrophin gene in many muscles of the body, including the heart, with the result that some muscles now had almost the normal amounts of dystrophin protein.
The team, led by Eric Olson, Ph.D., professor and chair of the Department of Molecular Biology at UTSW Medical Center and founder and chief science advisor of Exonics Therapeutics, and Richard Piercy, Ph.D., MRCVS, Professor of Comparative Neuromuscular Disease at the RVC, identified a naturally-occurring mutation in the dystrophin gene in a dog brought to the RVC’s Small Animal Referral Hospital.
Working now with relatives of this first dog, the combined group has used a technique called ‘SingleCut CRISPR gene editing’, where the researchers target a specific region of the subject’s own DNA. Harmless viruses encoding the gene-editing protein CRISPR/Cas9 were used to express the enzyme in muscle to cut the dogs’ own DNA at a precise location in the dystrophin gene through use of a molecular guide. The body’s own processes then repair the cut, which results in removing the negative effects of the existing mutation.
The researchers have demonstrated that dogs treated in this way had restored ability to produce large amounts of the dystrophin protein in their muscles and heart, and in the dog with the highest dose, cardiac muscles were found to have restored dystrophin protein to up to 92% of normal amounts after the single treatment.
The team believes this is the first time that this form of gene editing therapy has been conducted after birth in an animal larger than a rodent. With further longer-term research, efficacy and safety testing, it is hoped that this breakthrough will have human application. This treatment may be a significant step toward developing a gene editing therapy to repair genetic mutations for DMD, as well as a range of diseases caused by genetic mutations.
Richard Piercy, Professor of Comparative Neuromuscular Disease at the RVC, said: "Researchers have been looking for an effective and durable treatment for Duchenne muscular dystrophy for many years. This SingleCut gene editing approach, pioneered by Dr. Eric Olson’s group, has the potential to be a one-time treatment that could restore dystrophin protein. It is hugely exciting that through a single intravenous injection we’ve been able successfully to modify the dogs’ own DNA so they start generating dystrophin protein again. There is more work to be done, but with this exciting breakthrough, we feel we are a significant step closer to finding an effective treatment.
"A great many genetic diseases affect humans, dogs and other species - many, like DMD - with tragic consequences and this form of gene editing treatment might well be applicable in many of them. We’re hopeful that we’re paving the way for future research into treating some of the most serious genetic conditions that affect us today."
The original editorial team of Daniel Brockman and David Holt has been joined by Gert ter Haar to produce a new edition which considers the substantial progress that has been made in this important field, including the challenges of treating airway abnormalities linked to brachycephalism, the constraints of complex bony anatomy and rich vascularity of the head when performing radical surgery, and the treatment of trauma.
The book includes a number of new techniques, including dorsal rhinotomy and total ear canal ablation.
The BSAVA says operative techniques, instructive photographs and full-colour illustrations remain a key feature of the manual, which is aimed at the general veterinary practitioner.
The BSAVA Manual of Canine and Feline Head, Neck and Thoracic Surgery, 2nd edition is available from the BSAVA website: www.bsava.com or by phone: 01452 726700.
The survey found that 51% of cat and dog owners didn't research their pets breed before buying. Of the 22% who then regretted their decision, 31% said it was because they didn’t have enough time to look after the animal, 18% because they turned out to be allergic to the animal, and 16% because they didn’t like their pet’s personality.
Apparently dog owners were more likely to regret their new pet (26%) than cat owners (16%).
Sainsbury’s has therefore launched the Pawfect Match tool, designed to help future pet owners to make informed decisions when choosing the most suitable breed for them. The pet picker asks you a number of questions about your circumstances and makes a number of suggestions based on how you answer.
Sainsbury's campaign is being fronted by Scott Miller MRCVS, who said: "I am saddened to hear that so many pet owners are regretting the animals they have chosen as companions. Dogs and cats come in all shapes and sizes, and have different temperaments. Looking after a pet is a huge commitment so it is important that people undertake adequate research before buying a pet to ensure it is a happy experience."
COMMENT
I tried Sainsbury's pet picker and it recommended a Basset Hound as the first choice. Fair enough. I always think they look like the living embodiment of the word 'hangdog', which is not really my cup of tea. Luckily, the tool makes more than one suggestion. One of the criteria I'd specified was 'quiet and calm', so the second recommendation, a whippet, was fine. But the third caught my eye. A Border Collie. What? Whaaaaaat? Quiet and calm? A Border Collie. Are you having a laugh? I thought Border Collies usually need to be sent to some sort of asylum.
Still, if Sainsbury's tool encourages more people to think harder about their choice, that's no bad thing. But they might like to rethink the Border Collie recommendation.
Ceva says this is the first time it has advertised Feliway Friends - designed to help cats live together in harmony - on television. It will be rotating the Feliway advert with one explaining the benefits of the Adaptil Calm On-the-Go Collar.
Both advertisements are 30 seconds long and the campaign runs until the end of June. It will target 24.5 million pet owners and will air on all Channel 4 and Channel 4 partner channels, including Channel 4, E4, More4, Film4, Drama, Good Food, Really, W and Home.
Abigail King, product manager for Feliway and Adaptil at Ceva, said: "Our summer TV advertising campaign will raise awareness of how Feliway Friends and Adaptil Calm On-the-Go Collar can help pets with behavioural issues and drive customers to veterinary practices for further information and to purchase product."
For further information, visit www.feliway.com or www.adaptil.com.
Currently Principal of the Royal Veterinary College, University of London, and previously Dean of the University of Glasgow’s School Of Veterinary Medicine, Stuart has been a member of RCVS Council since 2005, and served as RCVS President in 2014-15.
As chair of the Education Policy and Specialisation Committee in 2011, Stuart oversaw the College’s review of veterinary specialisation, which also led to the new Advanced Practitioner status.
He has also been a driving force behind the joint RCVS and BVA Vet Futures project since its inception in 2015.
As Chair of the RCVS Governance Panel, he recently saw through reform of the College’s governance arrangements to improve the efficiency and accountability of its decision-making processes.
Stuart has also chaired the RCVS Science Advisory Panel.
He continues to chair the College’s Mind Matters Initiative, which aims to improve the mental health and wellbeing of all those in the veterinary team.
A particularly notable achievement during his Presidential year was to allow UK veterinary surgeons to use the courtesy title ‘Doctor’ if they so wished.
Lizzie Lockett, RCVS Chief Executive said: "We have been incredibly fortunate to have someone of Stuart’s calibre, character and international renown on our Council for so many years. His contributions and commitment to the RCVS, as well as to the wider veterinary professions, are as significant as they are often understated.
"On behalf of RCVS Council and all the staff, I should like to say how delighted we are that he has been honoured in this way. Such recognition is very much deserved and we send him our warmest congratulations."
Lucy and Rosanna have joined the business in hybrid positions as Novice OVs and will do this alongside working in a clinical practice.
The company says this is a significant milestone for the industry, which has relied on overseas talent for many years.
Eville & Jones says it has now developed a compelling proposition for UK new graduates who want to combine OV work with traditional clinical practice, and vets looking for a lifestyle change or a move away from practice, working flexibly in export certification, abattoir work, certification against standards, or small animal vaccination.
Charles Hartwell, chief executive officer of Eville & Jones said: “The team at Eville & Jones has spent two years developing an attractive proposition to encourage UK-educated veterinary surgeons to consider a career in this field, whether combined with traditional clinical practice, or stand alone.
"We wish Lucy and Rosanna the best of luck and hope they become trailblazers for many others to follow in their footsteps.”
Lucy said: “I’m really excited to be starting my career in veterinary public health where, as an OV, you can positively affect the lives of 1000’s of animals."
Rosanna added: “I’m really proud to have joined the veterinary industry this summer; OVs are instrumental in monitoring and safe-guarding animal welfare in a way that many vets don't realise."
I invited Marc Abraham to come and answer some of the concerns raised on VetSurgeon about the ITV Pets Undercover programme.
His PR agency has instead pointed me in the direction of a response he has posted on his own website this morning. Click the link below.
http://www.marcthevet.com/response-to-%e2%80%98pets-undercover%e2%80%99/
Bayer Animal Health (makers of Advocate, Advantix, Advantage, Seresto, Profender, Drontal and Droncit) has launched 'It's a Jungle Out There', an educational initiative aimed at simplifying parasite control for veterinary practices and pet owners alike.
The impressive-looking initiative comes on the back of research carried out by the company which found:
Dan White, Group Product Manager for Bayer's Animal Health division said: "Our research concluded that many vet practices are missing an opportunity because of a lack of clarity regarding best practice for parasite control. With ongoing support and practical development tools, Bayer's 'It's a Jungle Out There' Programme is an educational initiative which will arm vet practices with the tools they need to make parasite control clearer and more accessible to owners, helping to ensure the UK is a nation of healthy parasite-free pets and happy owners."
Bayer says the first stage of the 'It's a Jungle Out There' initiative aims to help the veterinary community identify opportunities where they can help to improve pet owner compliance. Vet practices will then be supported in developing a parasite protocol which will then be launched to consumers via a heavyweight advertising and PR campaign.
The initiative comprises a new educational website: www.jungleforvets.co.uk, which includes practice development workbooks, market research and trends, extensive technical information on a wide variety of parasites and CPD assessments. Additional downloadable content includes a range of materials such as images, videos, downloads and web buttons.
From the end of August, practice support materials will be available including a waiting room display pack, parasite guide and dispenser, vet nurse reference guide, waiting room posters, lifestyle questionnaire, badges and static window stickers.
The pet owner focus will begin in September and will include an interactive website, advertising and an extensive print and broadcast PR campaign with celebrity ambassadors David Bellamy and TV vet Steve Leonard. This activity is aimed at driving owners towards their vet practice for advice on parasite risks.
Nine-year-old Nigel the puma, from Lincolnshire Wildlife Park, was suffering from a deteriorating arthritic condition, which was causing loss of function in his front leg.
His veterinary team consulted an orthopaedic specialist and trialled medical management including steroids and Solensia, but Nigel was unresponsive to treatment.
This led to a severe debilitating limp and pain, leaving a choice between amputation or euthanasia.
Nigel's treatment was funded by donations from visitors to Lincolnshire Wildlife Park, which is a registered charity that was originally established as a sanctuary for parrots in the early 1990s, who raised nearly £5,000 following a fundraising campaign.
The operation took place in a sterile theatre set up in Nigel’s enclosure, where the entire limb was removed, including the scapula.
After an intense five-hour operation, led by Iain Cope, veterinary surgeon and practice owner at Vets4Pets Newmarket, and Shannon Grimwood, veterinary nurse at Vets4Pets Newmarket, Nigel is now on the road to recovery and adapting well to life with three legs.
Iain said: “Nigel’s case was certainly unique and one we haven’t come across before. Working alongside Lincolnshire Wildlife Park and a team of local vets and veterinary nurses, we applied our knowledge of domestic cat amputations to a big one.
“The approach was extremely similar, and the operation ran as smoothly as possible.”
The newsletter will include anaesthesia updates, bulletins and recaps, access to videos and downloadable resources.
Articles in Anaesthesia1ST are being written by Jurox’s technical advisors in collaboration with anaesthesia specialists such as Carl Bradbrook (European Veterinary Specialist in Anaesthesia and Analgesia and an RCVS Recognised Specialist in Veterinary Anaesthesia) and Ian Self (European Specialist in Veterinary Anaesthesia and Analgesia, Associate Professor in Veterinary Anaesthesia and Analgesia, Faculty of Medicine & Health Sciences, University of Nottingham).
The first newsletter launched on 15th May and included: ‘Capnography I – not just a load of hot air’, ‘Perspectives on premeds – Alpha-2 agonists’ and ‘What’s new in anaesthesia? Highlights of recent preoxygenation paper’.
Articles in future editions will include: ‘Capnography II – what happened to the elephants?’, ‘Pain, what a pain! Local and regional nerve blocks improve outcomes and welfare of patients’, “The Big Chill – temperature management in sedated and anaesthetised patients’ and ‘Perspectives on premeds – a complete series of articles covering the ins and outs of the different agents, how they compare and recommended use in the different patient types’.
Jurox says that downloadable resources will include a capnography cheat-sheet detailing different traces and their meaning, premedication drugs comparison tables and pre and post rabbit anaesthesia check-lists.
Richard Beckwith, country manager of Jurox (UK) Ltd, said: "We take great pride in our investment in educational initiatives to enable veterinary professionals to deliver best practice anaesthesia to their clients. The new Anaesthesia1ST newsletter further demonstrates our commitment to educational support resources to enable veterinary professionals to attain and maintain 1ST class anaesthesia for all patients."
To sign up to the Anaesthesia1ST newsletter, click here, visit the Alfaxan website – www.alfaxan.co.uk, contact your local Jurox technical sales representative or email Jurox at: info@jurox.co.uk.